(R-4) where Ra - hydrogen, -COOC1-C4-alkyl, Z, -COC5H4N3, -SO2-naphthyl or -COCH2H(Y)CH2CH2NH-Y where Y - hydrogen, Boc or Z; Rb - a group of the formula -C(NH)(CH2)0-3CH3 or , or if Ra a group of the formula -COC6H4N3, -SO2 -naphthyl or -COCH2N(Y)CH2CH2NHY then Rb - amidino-group where n = 1 or O, L - amino-group, or if n = 1 then L is also -(CH2)0-3-CH3; T - a group of the formula -CH2-(O)n, n = 1 or -CH(Rd)-CH2 or -CH2CO-; one of carbonyl-group in T-group can be in the form of ketal; Rd - hydrogen or NHRa or R=H, or COR0, R0- -NH0C1-4 -alkyl, -NH(CH2)1-4-C0H4Hal, -NHC0H4COOH, or radical linked over amino-group of -aminocarboxylic acid, or their physiologically acceptable salt. Reagent 1: compound of indicated above formula with protected amino-groups: Phe, Ala - t-butylhydroxycarbonyl, Asp, Val - ot-butyl, Arg-benzylhydroxycarbonyl, Ala - benzyl. Reagent 2: clearing one. Synthesized compounds show low toxicity and show high capability to inhibit fibrinogen binding. Synthesized compounds are used in biochemistry. EFFECT: enhanced effectiveness of compounds indicated above. 1 tbl"/> GLYCINE DERIVATIVES OR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS SHOWING CAPABILITY TO INHIBIT FIBRINOGEN BINDING IN FIBRINOGEN PLATELET RECEPTOR
首页> 外国专利> GLYCINE DERIVATIVES OR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS SHOWING CAPABILITY TO INHIBIT FIBRINOGEN BINDING IN FIBRINOGEN PLATELET RECEPTOR

GLYCINE DERIVATIVES OR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS SHOWING CAPABILITY TO INHIBIT FIBRINOGEN BINDING IN FIBRINOGEN PLATELET RECEPTOR

机译:甘氨酸衍生物或其生理上可接受的盐显示出抑制纤维蛋白原血小板受体中纤维蛋白原结合的能力

摘要

FIELD: organic chemistry. SUBSTANCE: derivatives of glycine of the general formula (I) R-CONH-CH2CONHCH(R)CH2COOH where R - a group of formula -CH(NHRa)-(CH2)1-6NH-Rb (R-1), (T)m-C6H4CH2NH2 (R-2), (T)m-C6H4(NH)nC(NH)-L (R-3) or (R-4) where Ra - hydrogen, -COOC1-C4-alkyl, Z, -COC5H4N3, -SO2-naphthyl or -COCH2H(Y)CH2CH2NH-Y where Y - hydrogen, Boc or Z; Rb - a group of the formula -C(NH)(CH2)0-3CH3 or , or if Ra a group of the formula -COC6H4N3, -SO2 -naphthyl or -COCH2N(Y)CH2CH2NHY then Rb - amidino-group where n = 1 or O, L - amino-group, or if n = 1 then L is also -(CH2)0-3-CH3; T - a group of the formula -CH2-(O)n, n = 1 or -CH(Rd)-CH2 or -CH2CO-; one of carbonyl-group in T-group can be in the form of ketal; Rd - hydrogen or NHRa or R=H, or COR0, R0- -NH0C1-4 -alkyl, -NH(CH2)1-4-C0H4Hal, -NHC0H4COOH, or radical linked over amino-group of -aminocarboxylic acid, or their physiologically acceptable salt. Reagent 1: compound of indicated above formula with protected amino-groups: Phe, Ala - t-butylhydroxycarbonyl, Asp, Val - ot-butyl, Arg-benzylhydroxycarbonyl, Ala - benzyl. Reagent 2: clearing one. Synthesized compounds show low toxicity and show high capability to inhibit fibrinogen binding. Synthesized compounds are used in biochemistry. EFFECT: enhanced effectiveness of compounds indicated above. 1 tbl
机译:领域:有机化学。物质:通式(I)的甘氨酸的衍生物R-CONH-CH 2 CONHCH(R)CH 2 COOH,其中R-通式为-CH(NHR)的基团 a )-(CH 2 1-6 NH-R b (R-1),(T ) m -C 6 H 4 CH 2 NH 2 (R-2 ),(T) m -C 6 H 4 (NH) n C(NH)-L( R-3)或(R-4),其中R a -氢,-COOC 1 -C 4 -烷基,Z,-COC 5 H 4 N < Sub> 3 ,-SO 2 -萘基或-COCH 2 H(Y)CH 2 CH 2 < / Sub> NH-Y,其中Y-氢,Boc或Z; R b -公式-C(NH)(CH 2 0-3 CH 3 ,或者如果R a 一组公式- COC 6 H 4 N 3 ,-SO 2 -萘基或-COCH 2 N(Y)CH 2 CH 2 NHY,然后R b -mid基,其中n = 1或O,L-氨基,或者如果n = 1,则L也是-(CH 2 0-3 -CH 3 ; T-一组式-CH 2 -(O) n ,n = 1或-CH(R d )-CH < Sub> 2 或-CH 2 CO-; T-基团中的羰基之一可以是缩酮形式。 R d -氢或NHR a 或R = H,或COR 0 ,R 0 --NH0C < Sub> 1-4 -烷基,-NH(CH 2 1-4 -C 0 H 4 Hal,-NHC 0 H 4 COOH或连接在-氨基羧酸氨基上的基团或其生理上可接受的盐。试剂1:具有被保护的氨基的上式所示化合物:Phe,Ala-叔丁基羟基羰基,Asp,Val-叔丁基,Arg-苄基羟基羰基,Ala-苄基。试剂2:清除一个。合成的化合物毒性低,抑制纤维蛋白原结合的能力强。合成的化合物用于生物化学。效果:增强上述化合物的有效性。 1汤匙

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号